NEUROD6: Key Regulator of Neural Development and Function (G63974)

Target Name: NEUROD6

NCBI ID: G63974

NEUROD6

NEUROD6: Key Regulator of Neural Development and Function

The basic helix-loop-helix (BHLH) gene is a key regulator of neural development and function. It encodes for the protein NEUROD6, which is a critical regulator of neuronal excitability and plays a key role in the development and maintenance of the nervous system.

NEUROD6 is a 21-kDa protein that is expressed in a variety of tissues, including brain, spinal cord, and peripheral tissues. It is primarily localized to the endoplasmic reticulum (ER) and is thought to play a role in regulating the levels of neurotransmitters, such as dopamine and GABA, in the nervous system.

One of the key functions of NEUROD6 is its role in modulating the strength of neural synapses. Neurons communicate with one another through the formation of synapses, which allow for the transfer of electrical signals. The strength of these synapses can be regulated by the levels of neurotransmitters, such as dopamine and GABA, which are released by the endostrils of the synapses.

NEUROD6 is known to play a key role in regulating the levels of these neurotransmitters in the nervous system. It does this by modulating the activity of several different proteins, including the neurotransmitter transporter SNAP250, which is responsible for transporting neurotransmitters out of the endostrils of the synapses.

In addition to its role in modulating neurotransmitter levels, NEUROD6 is also involved in the regulation of several other cellular processes that are critical for the proper functioning of the nervous system. For example, it is known to play a key role in the regulation of cell growth, cell survival, and the formation of neural circuits.

The ability of NEUROD6 to modulate the levels of neurotransmitters and other cellular processes makes it an attractive drug target for researchers. There is a growing body of research focused on identifying potential small molecules that can modulate the activity of NEUROD6, with the goal of developing new treatments for a variety of neurological and psychiatric disorders.

In addition to its potential as a drug target, NEUROD6 is also a valuable biomarker for the diagnosis and treatment of neurological and psychiatric disorders. The levels of NEUROD6 are often reduced in a variety of neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression.

Importantly, the levels of NEUROD6 can also be affected by environmental factors, such as exposure to toxins or radiation. This makes it possible to use NEUROD6 as a potential biomarker for the diagnosis and treatment of environmental stress-induced neurological disorders.

Overall, the basic helix-loop-helix (BHLH) gene is a key regulator of neural development and function, and the protein NEUROD6 is a critical regulator of neuronal excitability and plays a key role in the development and maintenance of the nervous system. The ability of NEUROD6 to modulate the levels of neurotransmitters and other cellular processes makes it an attractive drug target for researchers, and its potential as a biomarker for the diagnosis and treatment of neurological and psychiatric disorders makes it an important target for further research.

Protein Name: Neuronal Differentiation 6

Functions: Activates E box-dependent transcription in collaboration with TCF3/E47. May be a trans-acting factor involved in the development and maintenance of the mammalian nervous system. Transactivates the promoter of its own gene (By similarity)

The "NEUROD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEUROD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets